Laboratoire de Microbiologie, Centre Hospitalier Victor Dupouy, Argenteuil, France.
Int J Antimicrob Agents. 1993;2(3):151-83. doi: 10.1016/0924-8579(93)90052-7.
The mechanism of action and the mechanism of resistance of the 4-quinolones are complex and poorly understood. The first barrier these molecules must cross is the bacterial outer membrane. In gram-negative species, 4-quinolones pass through either the porins or lipopolysaccharides (or both) depending on their chemical nature. The cellular target is the DNA of the bacterial chromosome. 4-Quinolones mainly modify the activity of topoisomerase II or DNA gyrase, but also that of topoisomerase I and IV. Any damage to the bacterial genome will induce a stress response which consists in the SOS response, chaperonin synthesis or the generation of oxygen free radicals. Peptidoglycan synthesis is also modified, as shown by the inhibition of PBP(3) activity. Mechanism of resistance involves mutations on gyrA and gyrB genes. gyrA Mutations on the chromosome are responsible for a high level of resistance due to a modification of the A subunit of DNA gyrase, mutations on gyrB gene are responsible for a low level of resistance; the combination of both mutations leads to a high level of resistance. Other mutations are responsible for increasing the MIC, such as a norA mutation in S. aureus. The antibacterial activity of the various molecules is different and, as a result, there is not a single mechanism of action or resistance, but rather a common trunk on which additional mechanisms are grafted.
喹诺酮类药物的作用机制和耐药机制复杂且尚未完全阐明。这些分子必须首先穿过细菌的外膜。在革兰氏阴性菌中,根据其化学性质,喹诺酮类药物可以通过孔蛋白或脂多糖(或两者兼有)穿过。细胞靶标是细菌染色体的 DNA。喹诺酮类药物主要修饰拓扑异构酶 II 或 DNA 回旋酶的活性,但也修饰拓扑异构酶 I 和 IV 的活性。任何对细菌基因组的损伤都会引起应激反应,包括 SOS 反应、伴侣蛋白合成或产生氧自由基。肽聚糖的合成也被修饰,这表现为 PBP(3)活性的抑制。耐药机制涉及gyrA 和 gyrB 基因的突变。染色体上的 gyrA 突变导致高水平耐药,这是由于 DNA 回旋酶 A 亚单位的修饰,gyrB 基因突变导致低水平耐药;两者突变的组合导致高水平耐药。其他突变负责增加 MIC,例如金黄色葡萄球菌中的 norA 突变。各种分子的抗菌活性不同,因此,不存在单一的作用机制或耐药机制,而是存在一个共同的主干,其上附加了其他机制。